Sort   by:  
 Page size 
UnknownSensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors.
Not available
S-EPMC8691370 | biostudies-literature
UnknownReal-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
Not available
S-EPMC11452463 | biostudies-literature
UnknownEffectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States.
Not available
S-EPMC12173046 | biostudies-literature
UnknownTreatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.
Not available
S-EPMC9357269 | biostudies-literature
Sort   by:  
 Page size